p53 expression and resistance against paclitaxel in patients with metastatic breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 129, Issue 5, 2003, Pages 295-302

  Schmidt, M ^a   Bachhuber, A ^a   Victor, A ^b   Steiner, E ^a   Mahlke, M ^a   Lehr, H A ^a   Pilch, H ^a   Weikel, W ^a   Knapstein, P G ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Breast cancer; Chemoresistance; Metastatic; p53; Paclitaxel

Indexed keywords

BETA TUBULIN; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0038051275     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-003-0430-1     Document Type: Article

References (44)

1. Arrick BA, Nathan CF (1984) Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 44:4224-422
2. Baselga J, Seidman AD, Rosen PP, Norton L (1997) HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 1 l[Suppl 2]:43-48
3. Bishop JF, Dewar J, Toner G, Smith J, Tattersall MH, Olver I, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R (1999) Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. JCO 17:2355-2364
4. Bradley G, Naik M, Ling V (1989) P-Glykoprotein expression in multidrug resistant human ovarian carcinoma cell lines. Cancer Res 49:2790-2796
5. Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F (2001) A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer 92:738-747
6. Chadderton A, Villeneuve D J, Gluck S, Kirwan-Rhude AF, Gannon BR, Blais DE, Parissenti AM (2000) Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells. Breast Cancer Res Treat 59:231-244
7. Das GC, Holiday D, Gallardo R, Haas C (2001) Taxol-induced cell cycle arrest and apoptosis: dose response relationship in lung cancer cells of different wild-type p53 status under isogenic condition. Cancer Lett 165:147-153
8. Derry WB, Wilson L, Jordan MA.(1995) Substoichiometric binding of taxol suppresses microtubule dynamics. Biochem 34:2203-2211
9. Dirven HA, van Ommen B, van Bladeren PJ (1994) Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 54:6215-6220
10. Eck L, Pavich D, Fruehauf JP (1993) MDR-1 expression by human ovarian tumors is associated with taxol resistance. Proc Am Assoc Cancer Res 34:232
11. Gan YB, Balturshot G, Millenbaughm NJ, Chen CT, Kalns JE, Lim C, Wientjes MG, Au JL (1995) P-Glykoproteinexpression in human tumors and its correlation with chemosensitivity to taxol and cell mobility. Proc Am Assoc Cancer Res 36:334
12. Gan YB, Wientjes MG, Au JL (1998) Relationship between paclitaxel activity and pathobiology of human solid tumors. Clin Cancer Res 4:2949-2955
13. Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T (2000) Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 19:3078-3085
14. Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL (1999) Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate and breast cancer. Cancer Chemother Pharmacol 44:143-151
15. Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB (1995) Altered expression of M beta 2, the class II beta-tubulin isotype, in an murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 270:31269-31275
16. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlboeck M, Gnant M, Steger G, Jakesz R (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 6:50-56
17. Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T (1997) p-53 independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci USA 94:9679-9683
18. Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH, Vermorken J, Giaccone G (1997) Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71787-795
19. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 satus and the efficacy of cancer therapy in vivo. Science 266:807-810
20. Luduena RF (1998) Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 178:207-275
21. Mallarino MC, Duran GE, Dumontet CM, Sikic BI (1995). Mechanisms of resistance in a human sarcoma cell line continuously selected with paclitaxel (Taxol, TAX) and SDZ PSC 833. Proc Am Assoc Cancer Res 36:320
22. Masanek U, Stammler G, Volm M (1997) Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin. Anti-Cancer Drugs 8:189-198
23. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf JP (1998) Levels of multidrug resistance (MDR-1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4:389-398
24. Meijer C, Mulder NH, De Vries EGE (1990) The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycin. Cancer Treat Rev 7:389-407
25. Michael M, Bishop JF, Levi JA, Bell DR, Zalcberg JR, Friedlander ML, Olver IN, Smith JG, Toner GC (1997) Australian multicenter phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy. Med J Austral 10:520-523
26. Milross CG, Mason K, Hunter NR, Chung VK, Peters LJ, Milas L (1996) Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88:1308-1314
27. Nicoletti MI, Valoti G, Giannakakou P, Zhan Z, Kim JH, Lucchini V, Landoni F, Mayo JG, Giavazzi R, Fojo T (2001) Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Clin Cancer Res 7:2912-2922
28. Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G (1998) Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 4:835-846
29. Oldham EA, Li C, Ke S, Wallace S, Huang P (2000) Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells. Int J Oncol 16:125-132
30. Orr MS, ÓConnor PM, Kohn KW (2000) Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells. J Natl Cancer Inst 92:987-994
31. Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M (1993) p53 mutation in B-cell chronic lymphocytic leukemias associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452-3459
32. Schiff PB, Fant J, Horwitz SB (1979). Promotion of microtubule assembly in vitro by taxol. Nature 277:665-667
33. Shiga H, Heath EI, Rasmussen AA, Trock B, Johnston PG, Forastiere AA, Langmacher M, Baylor A, Lee M, Cullen KJ (1999) Prognostic value ofp53, glutathione-S-transferase π, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 5:4097-4104
34. Shimizu C, Fukutomi T, Tsuda H, Akashi-Tanaka S, Watanabe T, Nanasawa T, Sugihara K (2000) c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 73:17-20
35. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK, Iacopetta BJ (1996) Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 27:1050-1055
36. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC (2000) E1A-mediated paclitaxel sensitisation in HER-2/neu-overexpressing ovarian cancer SKOV3.ipl through apoptosis involving the caspase-3 pathway. Clin Cancer Res 6:250-259
37. van Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM, Giaccone G (1998) Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 5:249-255
38. van Poznak C, Tan L, Panageas KS, Arroyo CD, Hudis C, Norton L, Seidmann AD (2002) Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. JCO 20:2319-2326
39. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA (1996) Loss of normal p53 function confers sensitisation to taxol by increasing G2/M arrest and apoptosis. Nature Med 2:72-79
40. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E (1995) Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Molec Med 1:506-526
41. Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, Tokue Y, Narabayashi M, Adachi I, Takashima S (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16:2401-2408
42. Yang X, Uziely B, Groshen S, Lukas J, Israel V, Russell C, Dunnington G, Formenti S, Muggia F, Press MF (1999) MDR1 gene expression in primary and advanced breast cancer. Lab Invest 79:271-280
43. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC (1996) Over-expression of c-erbB-2/neu in breast cancer cells confers increased resistance to taxol via mdr-1-independent mechanisms. Oncogene 13:1359-1365
44. Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC (1999) Tyrosise kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitises these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 5:343-353